With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

Attivare Therapeutics, a Harvard startup out of the Wyss Institute, has licensed a portfolio of immune-modulating biomaterial technologies from Harvard University that was created at the Wyss Institute, John A. Paulson School of Engineering and Applied Sciences (SEAS), Dana-Farber Cancer Institute, and Massachusetts General Hospital. This technology creates an in vivo training ground for the immune system to fight cancer more effectively and prevent infection.

Harvard researchers have pioneered a groundbreaking method for generating large numbers of adult skeletal-muscle satellite cells, also known as muscle stem cells, in vitro.

The Wyss Institute at Harvard University announced that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system.